Results 21 to 30 of about 31,151 (261)
Engineering virus-like particles as vaccine platforms [PDF]
Current Opinion in Virology, 2016 Virus-like particles (VLPs) have been utilized as vaccine platforms to increase the immunogenicity of heterologous antigens. A variety of diverse VLP types can serve as vaccine platforms, and research has focused on engineering VLPs to improve their efficacy as vaccines, enhance their stability, and allow for more versatile display of antigens.
Kathryn M Frietze +2 more
openaire +2 more sources
Communications Biology, 2022 Cryo-EM structures reveal the role of glutathione (GSH) in poliovirus (PV) serotype 3 virus-like particle (VLP) stability, suggesting GSH or an analogous tight-binding antiviral offers potential for stabilizing VLP vaccines against PV.
Mohammad W. Bahar +10 more
doaj +1 more source
Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
Vaccines, 2020 Flaviviruses include several medically important viruses, such as Zika virus (ZIKV), Dengue virus (DENV), West Nile virus (WNV) and Japanese encephalitis virus (JEV).
Naru Zhang +3 more
doaj +1 more source
Advances in Virus-Like Particle Vaccines for Filoviruses [PDF]
The Journal of Infectious Diseases, 2011 Ebola virus (EBOV) and Marburg virus (MARV) are among the deadliest human pathogens, with no vaccines or therapeutics available. Multiple vaccine platforms have been tested for efficacy as prophylactic pretreatments or therapeutics for prevention of filovirus hemorrhagic fever.
Kelly L, Warfield, M Javad, Aman
openaire +2 more sources
Escherichia coli-derived virus-like particles in vaccine development
npj Vaccines, 2017 Recombinant virus-like particle-based vaccines are composed of viral structural proteins and mimic authentic native viruses but are devoid of viral genetic materials. They are the active components in highly safe and effective vaccines for the prevention
Xiaofen Huang +4 more
doaj +1 more source
Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
Frontiers in Immunology, 2018 It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a ...
Yong Gao +2 more
doaj +1 more source
Virus‐like particles for vaccination against cancer [PDF]
WIREs Nanomedicine and Nanobiotechnology, 2019 AbstractActive immunotherapy of cancer aims to treat the disease by inducing effective cellular and humoral immune responses. Virus‐like particle‐based vaccines have evolved dramatically over the last few decades, greatly reducing morbidity and mortality of several infectious diseases and expectedly preventing cervical cancer caused by human papilloma ...
Mona O. Mohsen +3 more
openaire +2 more sources
Exosomes-based particles as inhalable COVID-19 vaccines
Biomedical Technology, 2023 Coronavirus disease 2019 (COVID-19), a severely spreading pandemic, has dramatically brought physiological and economical burdens to people. Although the injectable vaccines have some achievements for coronavirus defense, they still generate accompanied ...
Lu Fan +3 more
doaj +1 more source
Next generation designer virus-like particle vaccines for dengue
Expert Review of Vaccines, 2019 Introduction: A safe and efficacious vaccine for dengue continues to be an unmet public health need. The recent licensing of a dengue vaccine (Dengvaxia) developed by Sanofi has brought to the fore the safety issue of vaccine-induced infection ...
Rahul Shukla +8 more
doaj +1 more source
Production of virus-like particles for vaccines
New Biotechnology, 2017 Virus-like particles (VLPs) are nanostructures that resemble the structures of viruses. They are composed of one or more structural proteins that can be arranged in several layers and can also contain a lipid outer envelope. VLPs trigger a high humoral and cellular immune response due to their repetitive structures. A key factor regarding VLP safety is
Fuenmayor, J., Gòdia, F., Cervera, L.
openaire +2 more sources